MultiPlan and major insurers sued for alleged medical price

AdobeMultiPlanisfacinganewclassactionlawsuitthatallegesthecompanyandlargehealthinsurers“conspiredtof AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha




leisure time

author：comprehensive    Page View：54651
UCB website -- health policy coverage from STAT
Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

advertisement

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Has Bernie Sanders reached the limit of his pharma bullying effort?
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts